✦ LIBER ✦

A trial of razoxane (ICRF-159) in patients with prior therapy for Modgkin's Lymphoma

✍ Scribed by Michael P. Corder; David B. McFadden; Shirley J. Bell

Publisher: John Wiley and Sons
Year: 1984
Tongue: English
Weight: 232 KB
Volume: 54
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19841015)54:8<1496::aid-cncr2820540803>3.0.co;2-4

No coin nor oath required. For personal study only.

✦ Synopsis

Razoxane (ICRF-159) was administered to 11 patients with Stage IV nodular sclerosing Hodgkin's lymphoma. A weekly schedule was employed with a starting dose of 1000 mg/m2 in divided doses. The dose was escalated up to 2000 mg/m2 weekly as tolerated. One objective partial remission was observed. The toxicity of the program was quite tolerable. Further trials of razoxane in this situation are not recommended.

📜 SIMILAR VOLUMES

Chemotherapy in patients with prostate s

Chemotherapy in patients with prostate specific antigen–only disease after primary therapy for prostate carcinoma : A Phase II trial of oral estramustine and oral etoposide

✍ Hidayatullah G. Munshi; Kenneth J. Pienta; David C. Smith 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 2 views

## BACKGROUND. A Phase II study was initiated to evaluate the effectiveness of an oral regimen of etoposide and estramustine in patients with early recurrent prostate carcinoma. ## METHODS. Patients with early recurrent prostate carcinoma as indicated by an increasing prostate specific antigen

Influence of anti–tumor necrosis factor

Influence of anti–tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for rheumatology biologics register

✍ W. G. Dixon; K. D. Watson; M. Lunt; L. K. Mercer; British Society For Rheumatolo 📂 Article 📅 2010 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 111 KB 👁 2 views